{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:55Z","timestamp":1790398795179,"version":"4.1.0"},"reference-count":49,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/ddt.2026.01050","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:11:17Z","timestamp":1787695877000},"page":"309-321","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the allosteric inhibition mechanism of SARS-CoV-2 main protease and discovery of a novel allosteric inhibitor"],"prefix":"10.5582","volume":"20","author":[{"given":"Quanling","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China."},{"name":"Shandong Key Laboratory of Pathogenesis and Prevention of Brain Diseases, Qingdao University, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Piret J, Boivin G. Pandemics throughout history. Front Microbiol. 2021; 11:631736.","DOI":"10.3389\/fmicb.2020.631736"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001; 32:675-685.","DOI":"10.1086\/319235"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020; 78:185-193.","DOI":"10.1016\/j.ijsu.2020.04.018"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Karniadakis I, Mazonakis N, Tsioutis C, Papadakis M, Markaki I, Spernovasilis N. Oral Molnupiravir and Nirmatrelvir\/Ritonavir for the treatment of COVID-19: a literature review with a focus on real-world evidence. Infect Dis Rep. 2023; 15:662-678.","DOI":"10.3390\/idr15060061"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cao B, Wang Y, Lu H, <i>et al.<\/i> Oral simnotrelvir for adult patients with mild-to-moderate COVID-19. N Engl J Med. 2024; 390:230-241.","DOI":"10.1056\/NEJMoa2301425"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chen X, Huang X, Ma Q, <i>et al<\/i>. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol. 2024; 9:1075-1088.","DOI":"10.1038\/s41564-024-01618-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Syed YY. Ensitrelvir fumaric acid: first approval. Drugs. 2024; 84:721-728.","DOI":"10.1007\/s40265-024-02039-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology. 2021; 29:1075-1090.","DOI":"10.1007\/s10787-021-00839-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Khobragade A, Bhate S, Ramaiah V, <i>et al.<\/i> Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022; 399:1313-1321.","DOI":"10.1016\/S0140-6736(22)00151-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hadj Hassine I. COVID-19 vaccines and variants of concern: a review. Rev Med Virol. 2022; 32:e2313.","DOI":"10.1002\/rmv.2313"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gra\u00f1a C, Ghosn L, Evrenoglou T, <i>et al.<\/i> Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022; 12:CD015477.","DOI":"10.1002\/14651858.CD015477"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. McLean G, Kamil J, Lee B, Moore P, Schulz TF, Muik A, Sahin U, T\u00fcreci \u00d6, Pather S. The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines. mBio. 2022; 13:e02979-21.","DOI":"10.1128\/mbio.02979-21"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Madhi SA, Baillie V, Cutland CL, <i>et al.<\/i> Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021; 384:1885-1898.","DOI":"10.1056\/NEJMoa2102214"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hu Q, Xiong Y, Zhu G, Zhang Y, Zhang Y, Huang P, Ge G. The SARS-CoV-2 main protease (Mpro): structure, function, and emerging therapies for COVID-19. MedComm. 2022; 3:e151.","DOI":"10.1002\/mco2.151"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bhardwaj M, Anjum R, Hariprasad P, Patel AK. Allosteric mutations impact the catalytic activity and oligomeric state of the main protease of coronavirus. Int J Biol Macromol. 2025; 309:142765.","DOI":"10.1016\/j.ijbiomac.2025.142765"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gioia M, Ciaccio C, Calligari P, De Simone G, Sbardella D, Tundo G, Fasciglione GF, Di Masi A, Di Pierro D, Bocedi A, Ascenzi P, Coletta M. Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. Biochem Pharmacol. 2020; 182:114225.","DOI":"10.1016\/j.bcp.2020.114225"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science. 2020; 368:409-412.","DOI":"10.1126\/science.abb3405"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Liu Y, Liang C, Xin L, Ren X, Tian L, Ju X, Li H, Wang Y, Zhao Q, Liu H, Cao W, Xie X, Zhang D, Wang Y, Jian Y. The development of coronavirus 3C-like protease (3CLpro) inhibitors from 2010 to 2020. Eur J Med Chem. 2020; 206:112711.","DOI":"10.1016\/j.ejmech.2020.112711"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Jin Z, Du X, Xu Y, <i>et al.<\/i> Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020; 582:289-293.","DOI":"10.1038\/s41586-020-2223-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cannalire R, Cerchia C, Beccari AR, Di Leva FS, Summa V. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities. J Med Chem. 2022; 65:2716-2746.","DOI":"10.1021\/acs.jmedchem.0c01140"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lu H, Zhang G, Mao J, <i>et al<\/i>. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2\/3 trial. eClinicalMedicine. 2024; 71:102582.","DOI":"10.1016\/j.eclinm.2024.102582"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hattori SI, Bulut H, Hayashi H, <i>et al<\/i>. Structural and virologic mechanism of the emergence of resistance to Mpro inhibitors in SARS-CoV-2. Proc Natl Acad Sci U S A. 2024; 121:e2404175121.","DOI":"10.1073\/pnas.2404175121"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Moghadasi SA, Biswas RG, Harki DA, Harris RS. Rapid resistance profiling of SARS-CoV-2 protease inhibitors. NPJ Antimicrob Resist. 2023; 1:9.","DOI":"10.1038\/s44259-023-00009-0"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on receptors. Annu Rev Pharmacol. 2014; 54:165-184.","DOI":"10.1146\/annurev-pharmtox-010611-134525"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Cimermancic P, Weinkam P, Rettenmaier TJ, Bichmann L, Keedy DA, Woldeyes RA, Schneidman-Duhovny D, Demerdash ON, Mitchell JC, Wells JA, Fraser JS, Sali A. CryptoSite: expanding the druggable proteome by characterization and prediction of cryptic binding sites. J Mol Biol. 2016; 428:709-719.","DOI":"10.1016\/j.jmb.2016.01.029"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Greener JG, Sternberg MJ. Structure-based prediction of protein allostery. Curr Opin Struct Biol. 2018; 50:1-8.","DOI":"10.1016\/j.sbi.2017.10.002"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. G\u00fcnther S, Reinke PYA, Fern\u00e1ndez-Garc\u00eda Y, <i>et al.<\/i> X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021; 372:642-646.","DOI":"10.1126\/science.abf7945"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Samrat SK, Xu J, Xie X, Gianti E, Chen H, Zou J, Pattis JG, Elokely K, Lee H, Li Z, Klein ML, Shi PY, Zhou J, Li H. Allosteric inhibitors of the main protease of SARS-CoV-2. Antiviral Res. 2022; 205:105381.","DOI":"10.1016\/j.antiviral.2022.105381"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Sch\u00f6nbrunn E. Structural basis of Wee kinases functionality and inactivation by diverse small molecule inhibitors. J Med Chem. 2017; 60:7863-7875.","DOI":"10.1021\/acs.jmedchem.7b00996"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Heged\u00fcs C, Truta-Feles K, Antalffy G, V\u00e1rady G, N\u00e9met K, Ozvegy-Laczka C, K\u00e9ri G, Orfi L, Szak\u00e1cs G, Settleman J, V\u00e1radi A, Sarkadi B. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012; 84:260-267.","DOI":"10.1016\/j.bcp.2012.04.010"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000; 28:235-242.","DOI":"10.1093\/nar\/28.1.235"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron. 2018; 99:1129-1143.","DOI":"10.1016\/j.neuron.2018.08.011"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Case DA, Aktulga HM, Belfon K, <i>et al.<\/i> AmberTools. J Chem Inf Model. 2023; 63:6183-6191.","DOI":"10.1021\/acs.jcim.3c01153"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Tian C, Kasavajhala K, Belfon KAA, Raguette L, Huang H, Migues AN, Bickel J, Wang Y, Pincay J, Wu Q, Simmerling C. ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J Chem Theory Comput. 2020; 16:528-552.","DOI":"10.1021\/acs.jctc.9b00591"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983; 79:926-935.","DOI":"10.1063\/1.445869"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Bayly CI, Cieplak P, Cornell W, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem. 1993; 97:10269-10280.","DOI":"10.1021\/j100142a004"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977; 23:327-341.","DOI":"10.1016\/0021-9991(77)90098-5"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Babin V, Roland C, Sagui C. Adaptively biased molecular dynamics for free energy calculations. J Chem Phys. 2008; 128:134101.","DOI":"10.1063\/1.2844595"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Wagner JR, S\u00f8rensen J, Hensley N, Wong C, Zhu C, Perison T, Amaro RE. POVME 3.0: software for mapping binding pocket flexibility. J Chem Theory Comput. 2017; 13:4584-4592.","DOI":"10.1021\/acs.jctc.7b00500"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kumari R, Kumar R, Lynn A. G_mmpbsa \u2013 a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014; 54:1951-1962.","DOI":"10.1021\/ci500020m"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Zoete V, Daina A, Bovigny C , Mich iel in O. SwissSimilarity: a web tool for low to ultra high throughput ligand-based virtual screening. J Chem Inf Model. 2016; 56:1399-1404.","DOI":"10.1021\/acs.jcim.6b00174"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Vilar S, Cozza G, Moro S. Medicinal chemistry and the Molecular Operating Environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem. 2008; 8:1555-1572.","DOI":"10.2174\/156802608786786624"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31:455-461.","DOI":"10.1002\/jcc.21334"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717.","DOI":"10.1038\/srep42717"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Fu L, Shi S, Yi J, Wang N, He Y, Wu Z, Peng J, Deng Y, Wang W, Wu C, Lyu A, Zeng X, Zhao W, Hou T, Cao D. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res. 2024; 52:W422-W431.","DOI":"10.1093\/nar\/gkae236"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Banerjee P, Kemmler E, Dunkel M, Preissner R. ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2024; 52:W513-W520.","DOI":"10.1093\/nar\/gkae303"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Kneller DW, Phillips G, O&apos;Neill HM, Jedrzejczak R, Stols L, Langan P, Joachimiak A, Coates L, Kovalevsky A. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun. 2020; 11:3202.","DOI":"10.1038\/s41467-020-16954-7"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Zhao J, Ma Q, Zhang B, Guo P, Wang Z, Liu Y, Meng M, Liu A, Yang Z, Du G. Exploration of SARS-CoV-2 3CLpro inhibitors by virtual screening methods, FRET detection, and CPE assay. J Chem Inf Model. 2021; 61:5763-5773.","DOI":"10.1021\/acs.jcim.1c01089"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Razzaq A, Disoma C, Zhou Y, <i>et al<\/i>. Targeting epidermal growth factor receptor signalling pathway: a promising therapeutic option for COVID-19. Rev Med Virol. 2024; 34:e2500.","DOI":"10.1002\/rmv.2500"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01050\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:30:15Z","timestamp":1790397015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01050\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01050","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01050"}}